Alana Hippensteele

Key Takeaways The FDA struggles with regulating rapidly advancing AI/ML technologies in medical devices, leading to regulatory gaps and challenges.

AI-powered drug response prediction technology is revolutionizing veterinary and human oncology by enabling personalized treatment plans through live cell testing, machine learning models, and data-driven precision medicine approaches.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses a study she conducted that highlights how social determinants of health exacerbate severity and increase rates of mortality from Clostridioides difficile infections in vulnerable communities.

The American Society of Hematology (ASH) Annual Meeting and Exposition will include the latest news and clinical trial updates in the hematology field.

Glucagon-like peptide 1 (GLP1) receptor agonists were shown to be associated with a reduced risk of venous thromboembolism (VTE), while high dietary fiber intake was shown to enhance microbiome health, lower graft-versus-host disease (GVHD) severity, and improve overall survival following allogeneic hematopoietic cell transplantation.

A ketogenic diet and its key metabolite, β-hydroxybutyrate, enhance the efficacy of CAR T-cell therapy by improving metabolic fitness, cytokine production, and cellular expansion, offering a promising, safe strategy for optimizing cancer immunotherapy.

The AQUILA study demonstrates that early treatment with daratumumab significantly delays progression to symptomatic multiple myeloma, improves survival outcomes, and offers a well-tolerated alternative to traditional observation.

The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).

The GMMG-HD7 trial evaluated the addition of isatuximab to standard induction therapy in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation, demonstrating significantly higher rates of minimal residual disease negativity and improved progression-free survival (PFS).

The phase 3 CEPHEUS trial demonstrated that adding daratumumab (DARA) to the VRd regimen significantly improves minimal residual disease negativity, progression-free survival, and overall response in transplant-ineligible or transplant deferred patients with newly diagnosed multiple myeloma, establishing a new standard of care.